SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing downward price pressure despite beating revenue and earnings expectations, primarily due to investor anxiety over a significant increase in capital expenditure guidance for 2026. The community remains deeply divided, with some investors viewing the dip as a high-conviction buying opportunity for a profitable AI leader, while others criticize management's massive infrastructure spending and persistent regulatory risks.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is at the center of intense market focus as investors await earnings, with the community closely tracking AWS growth and the company's massive capital expenditure for AI infrastructure. The stock has seen significant call-side conviction and bullish sentiment, as participants look for a clear signal on how these aggressive investments are translating into cloud monetization and long-term profitability.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing volatility as investors weigh a strong earnings beat, fueled by accelerating Azure growth and massive AI momentum, against concerns over the significant capital expenditure required to scale data center capacity. The community remains sharply divided, with bulls pointing to the company's long-term leadership in the AI infrastructure race while bears express frustration over the stock's price action and the sustainability of massive, debt-financed spending.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as it hits fresh record highs, driven by massive investor optimism surrounding its AI stack and record-breaking cloud results that silenced previous skepticism. The community is focused on the company's ability to turn heavy capital expenditures into tangible revenue growth, positioning it as a standout performer compared to other mega-cap peers currently struggling with rising infrastructure costs.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly shares are in focus as the company recently launched its oral GLP-1 pill, Foundayo, triggering intense community debate over its clinical efficacy and safety profile compared to Novo Nordisk's established offerings. Investors are closely monitoring the stock ahead of upcoming earnings as the market scrutinizes the company's competitive position and recent oncology-focused acquisitions.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is seeing heightened market attention following strong quarterly results that showcased record-breaking cloud performance and Search strength driven by the successful integration of its full-stack AI technology. The community is actively discussing Google's aggressive AI capital expenditures and strategic partnerships with firms like Anthropic, with analysts frequently raising price targets as the company demonstrates measurable returns on its heavy infrastructure investments.

Huachen AI Parking Management Technology Holding Co., Ltd. engages in the provision of smart parking solutions and equipment structural parts. Its products include structural parts, garage structural parts, materials such as customized steel and load bearing steel plates for cubic parking equipment, and railroad accessories. The company was founded by Lu Bin on September 30, 2021 and is headquartered in Jiaxing, China.

Huachen AI Parking Management Technology Holding Co. Ltd. - Ordinary Shares - Class A

Huachen AI Parking Management Technology Holding Ord Shs

Huachen AI Parking Management Technology is experiencing significant volatility and high retail engagement, driven by a reverse stock split that has drastically reduced the float and triggered intense speculation about a potential short squeeze. Investors are actively debating the sustainability of this momentum, drawing comparisons to other recent low-float Chinese equity runners while monitoring price levels for potential breakout or reversal.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is trending due to a notable contract win with a U.S. defense contractor, which has fueled investor enthusiasm for its specialized radiation-resistant memory technology. The community is actively discussing the stock's potential for significant growth as a key player in edge AI and defense infrastructure, with many participants focused on its role as a strategic memory supplier.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors pivot toward the company as a potential data center power solution, fueled by bullish sector sentiment from peer earnings and a rapidly growing business development pipeline. While the community is actively debating the stock's future, discussions are polarized between those betting on an AI-driven infrastructure 'catch-up' play and skeptics concerned about the company's historical challenges with profitability and dilution.

Addentax Group Corp. is a holding company, along with its subsidiaries, engages in the textile and garments industry. It operates through the following segments: Garment Manufacturing, Logistics Services, and Property Management and Subleasing. The Garments Manufacturing segment focuses on manufacturing and distribution of garments. The Logistics Services segment includes delivery and courier services covering some provinces in China. The Property Management and Subleasing segment offers services for wholesalers and retailers. The company was founded on October 28, 2014 and is headquartered in Shenzhen, China.

Addentax Group Corp

Addentax Group Corp (ATXG) is currently trending due to its volatile, low-float structure and recent strategic fintech acquisition news that has drawn intense interest from retail traders. The community is actively debating the stock's potential for rapid price swings, with many traders drawing parallels to other recent China-based micro-cap runners and short-squeeze setups.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher - Time to Buy?

Polaryx Therapeutics (NASDAQ:PLYX) Shares Up 4.9% - Here's Why...

Polaryx Therapeutics (NASDAQ:PLYX) Stock Price Down 1.9%  - Time to Sell?

Polaryx Therapeutics (NASDAQ:PLYX) Trading Down 1.9% - Time to Sell...

<ul class="summary-bullets"><li>Polaryx Therapeutics went public via a direct listing on Feb. 2.</li><li>The biotech firm is developing treatments for lysosomal storage disorders (LSDs).</li><li>Stocktwits sentiment for PLYX shifted to ‘extremely bullish’ after the stock rally.</li></ul><p>Shares of Polaryx Therapeutics (PLYX), a newly listed clinical-stage biotech firm, surged 70% on Tuesday,&nbsp;its best session on record, spurring increased interest from retail traders on Stocktwits. The micro-cap stock surged 29% on Monday.</p><h2 class="st-heading-2"><strong>Biotech Stocks Drawing Interest</strong></h2><p>Polaryx is focused on rare neurodegenerative diseases and is currently testing its PLX-200 treatment aimed at treating lysosomal storage disorders (LSDs), genetic diseases where the body can’t break down certain molecules, causing harmful buildup inside cells.</p><p>Biotech names have been catching investors' eyes as they seek shelter from the market turbulence triggered by the US-Israel conflict with Iran. Drug stocks have emerged as a go-to safe haven amid all the geopolitical uncertainty this year: the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF</a> (XBI) has gained over 4% this year while the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust</a> (SPY) and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust Series 1</a> (QQQ) index funds (which track the benchmark U.S. indices) have shed about 1%.</p><p>Polaryx’s pipeline includes four drug candidates, namely, PLX-200, PLX-100, PLX-300, and PLX-400 for LSDs. The last three are still in the preclinical stage.</p><h2 class="st-heading-2"><strong>Recent Updates From PLYX</strong></h2><p>The recent uptrend in the stock was likely triggered as investors took note of the company’s research advances. The company&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nasdaq.com/articles/polaryx-initiate-soteria-phase-2-basket-trial-1h2026-stock?utm_source=chatgpt.com">announced</a> on Feb. 17 that it was moving forward with its phase-2 trial evaluating PLX-200 in four lysosomal storage disorders (LSDs) after receiving a “safe-to-proceed” letter from the Food and Drug Administration in October.</p><p>Last week, Maxim initiated coverage on the PLYX with a ‘Buy’ rating and $10 price target, which implies a 66% upside to the stock’s last close. The firm said it views PLX-200 as a differentiated offering, given its oral formulation and potential to address a broad spectrum of LSDs by targeting shared disease pathways.</p><h2 class="st-heading-2"><strong>Retail’s View On PLYX</strong></h2><p>On Stocktwits, retail sentiment for PLYX shifted to ‘extremely bullish’ as of early Wednesday, from ‘bullish’ the prior day, amid ‘extremely high’ message volume. The watcher count for&nbsp;<a href="https://stocktwits.com/symbol/PLYX">PLYX</a> on the platform increased nearly 50% over the past 24 hours.</p><p>Several users&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.stocktwits.com/NorthernMonkey1/message/647157001">said</a> they would be watching the stock in the coming days.</p><p>“$PLYX development stage biotech that traders tend to position in ahead of pipeline progress updates. These setups usually need sustained volume to get momentum going,” one trader&nbsp;<a href="https://stocktwits.com/topstockalerts/message/647155307">said</a>, explaining the prevailing view.</p><p>About 25 million PLYX shares exchanged hands on Tuesday, about nine times the stock’s average trading volume, according to Stocktwits data.</p><h2 class="st-heading-2"><strong>Stock Widely Down Since Listing</strong></h2><p>Polaryx’s recent gains come&nbsp;as a relief, as the stock slid sharply after its direct listing on the Nasdaq on Feb. 2. Shares currently trade at about one-tenth of their opening price of $45.00 that day.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-shuts-up-the-bears-as-ceo-touts-faster-cheaper-ai-wall-street-is-totally-buying-it/cZdANc5RIJT">Oracle Shuts Up The Bears As CEO Touts 'Faster, Cheaper' AI: Wall Street Is Totally Buying It</a></p>

Traders work on the floor of the New York Stock Exchange.

Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest?

Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day.

PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech

Equity

Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day.


Maxim Group Begins Coverage on Polaryx Therapeutics (NASDAQ:PLYX)

Maxim Group began coverage on Polaryx Therapeutics in a report on Friday. They set a "buy" rating and a $10.00 price objective on the stock...

Polaryx Therapeutics (NASDAQ:PLYX) Shares Up 15.2% - Here's Why

Polaryx Therapeutics (NASDAQ:PLYX) Shares Up 15.2% - Here's Why...

What's Going On With Polaryx Therapeutics Stock Wednesday?

Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement.read more...

Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans

Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial to evaluate lead candidate for lysosomal storage disorders.read more...

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Polaryx Therapeutics Inc.

$GOOGL

$MSFT

$AMZN

$META

Which Mag 7 name makes the biggest move after earnings today?

Current Price	$5.22
Prev Close	$5.63
Open	$5.63
Dividend Yield	N/A
50-Day Moving Average	$5.08
Beta	0.36
Avg. Volume	2.17M
PE Ratio	-27.50

52-Week High	$48.91
52-Week Low	$2.20
Market Capitalization	$247.13M
EPS (Annual)	-$0.1898
Price to Book	54.14
Revenue Per Employee	$0.00

PLYX
Polaryx Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest PLYX News

PLYXPolaryx Therapeutics Inc.